Piper Sandler Forecasts Strong Price Appreciation for Becton, Dickinson and Company (NYSE:BDX) Stock

Key Points

• Piper Sandler raised its BDX price target from $175 to $200 but kept a neutral rating; at the share price cited in the article, its target implied 6.12% downside.
• BD reported quarterly EPS of $4.15 and revenue of $5.27 billion, both above analyst expectations, with revenue up 5.4% year over year. The company also authorized repurchases of up to 10 million shares and raised its quarterly dividend by 1%.
• Despite the results beat, concerns about subdued fiscal 2027 revenue-growth guidance reportedly weighed on the outlook and tempered the positive news.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) had its price target upped by stock analysts at Piper Sandler from $175.00 to $200.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a "neutral" rating on the medical instruments supplier's stock. Piper Sandler's price target would suggest a potential downside of 6.12% from the company's current price.

Several other research analysts have also recently weighed in on BDX. Jefferies Financial Group restated a "buy" rating and set a $242.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. UBS Group initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target on the stock. Royal Bank Of Canada boosted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Finally, Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $188.87.

Becton, Dickinson and Company Stock Up 1.8%

Shares of BDX opened at $213.05 on Friday. The firm has a fifty day moving average price of $187.69 and a 200-day moving average price of $170.23. The firm has a market capitalization of $58.70 billion, a P/E ratio of 64.17, a P/E/G ratio of 14.10 and a beta of 0.22. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $214.78. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company's revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.96 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase program on Thursday, November 5th that authorizes the company to buy back 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company's stock, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of BDX. PBU The Pension Fund of Early Childhood & Youth Educators boosted its stake in shares of Becton, Dickinson and Company by 6.4% in the 3rd quarter. PBU The Pension Fund of Early Childhood & Youth Educators now owns 82,349 shares of the medical instruments supplier's stock valued at $14,740,000 after buying an additional 4,958 shares during the period. CENTRAL TRUST Co boosted its stake in Becton, Dickinson and Company by 54.6% in the third quarter. CENTRAL TRUST Co now owns 1,510 shares of the medical instruments supplier's stock valued at $270,000 after acquiring an additional 533 shares in the last quarter. Fifth Third Bancorp increased its position in Becton, Dickinson and Company by 13.9% during the third quarter. Fifth Third Bancorp now owns 119,395 shares of the medical instruments supplier's stock worth $21,372,000 after buying an additional 14,579 shares during the period. Bayban raised its holdings in shares of Becton, Dickinson and Company by 74.0% in the third quarter. Bayban now owns 214 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 91 shares during the last quarter. Finally, New Mexico Educational Retirement Board grew its stake in shares of Becton, Dickinson and Company by 14.8% in the 3rd quarter. New Mexico Educational Retirement Board now owns 16,266 shares of the medical instruments supplier's stock valued at $2,912,000 after purchasing an additional 2,100 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q4 adjusted EPS of $4.15 and revenue of $5.3 billion topped estimates; revenue grew 5.4% year over year. For FY2026, free cash flow rose 42.5% to $2.9 billion, a sign of improved cash generation. BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
• Positive Sentiment: BD authorized repurchases of up to 10 million shares—about 3.6% of shares—and raised its quarterly dividend 1% to $1.06, extending its annual dividend-increase streak to 55 years. BD Board Increases Dividend and Authorizes Share Repurchases
• Positive Sentiment: Evercore ISI raised its price target to $230 from $210, indicating a more favorable analyst view. Evercore ISI Adjusts Becton, Dickinson and Company Price Target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: revenue growth guidance was viewed as subdued and slightly below expectations, tempering the impact of the quarterly beat and prompting a negative reaction in premarket trading. BD Q3 CY2026 Beats on Revenue, but Full-Year Guidance Comes in Below Expectations

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.